PortViewPortView
ARS Pharmaceuticals logo

ARS Pharmaceuticals (SPRY) Stock Analysis

NASDAQHealthcareBiotechnology

$3.62-2.83%
1-year price historyRange $3.62 – $13.06
52-week range$3.62
$3.53$13.15

Track SPRY in your portfolio for free · Portfolio tracker

What ARS Pharmaceuticals does

ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology. This product serves as a crucial intervention for individuals and their households who are susceptible to life-threatening allergic reactions caused by food, pharmaceuticals, or insect stings. Among its offerings is Neffy, a low-dose version of its intranasal epinephrine nasal spray. Established in 2015, the firm operates out of San Diego, California.

Key metrics

Market cap
$360.43M
P/E (TTM)
-1.66
EPS (TTM)
$-2.18
Beta
0.88
Dividend yield
0.00%
Revenue / share
$1.18
50-day avg
$4.72
200-day avg
$7.51
52-week high
$13.15
52-week low
$3.53
CEO
Donn Casale

ETFs linked to SPRY

Broad-market and Healthcare sector ETFs an investor holding ARS Pharmaceuticals is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how SPRY fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze SPRY in PortView →

Similar companies

Frequently asked questions

What is the ticker symbol for ARS Pharmaceuticals?
ARS Pharmaceuticals trades under the ticker SPRY on NASDAQ.
Which exchange is SPRY listed on?
SPRY is listed on NASDAQ.
What sector does ARS Pharmaceuticals operate in?
ARS Pharmaceuticals is classified in the Healthcare sector (Biotechnology industry).
How can PortView help analyze SPRY in a portfolio?
PortView shows SPRY's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.